RxDoctor Payments Data

Casey Wong, MD

Cardiovascular Disease · Princeton, NJNPI 1104143148

Payments from drug & device makers

$827in general payments, 2019–2025

Across 23 payments — averaging $35.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Impulse Dynamics (USA) Inc.$338
  • Johnson & Johnson$178
  • Medtronic$149
  • Amgen$56
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$49
  • Boehringer Ingelheim$26
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$77293%
  • Education$567%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$827 in reported general payments places this provider in the 25th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$700,653
Medicare patients
1,234
Services billed
6,665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban846$1,109,330
EntrestoSacubitril/Valsartan216$293,424
XareltoRivaroxaban169$239,589
FarxigaDapagliflozin Propanediol103$130,739
Repatha SureclickEvolocumab30$32,543
Nebivolol Hcl311$20,242
Icosapent Ethyl37$18,146
Metoprolol Succinate824$14,088
Atorvastatin Calcium991$13,100
JardianceEmpagliflozin13$10,109
Flecainide Acetate117$6,702
Rosuvastatin Calcium363$6,209
Pitavastatin Calcium12$5,584
Amlodipine Besylate648$5,437
Dofetilide46$5,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$178$239,589169 claims
Boehringer IngelheimJardiance$26$10,10913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Princeton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →